The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014

Michael J. Brennan, Rachel Tanner, Sheldon Morris, Thomas J. Scriba, Jacqueline M. Achkar, Andrea Zelmer, David A. Hokey, Angelo Izzo, Sally Sharpe, Ann Williams, Adam Penn-Nicholson, Mzwandile Erasmus, Elena Stylianou, Daniel F. Hoft, Helen McShane, Helen A. Fletcher

Research output: Contribution to journalShort survey

9 Citations (Scopus)

Abstract

The development of a functional biomarker assay in the tuberculosis (TB) field would be widely recognized as a major advance in efforts to develop and to test novel TB vaccine candidates efficiently. We present preliminary studies using mycobacterial growth inhibition assays (MGIAs) to detect Mycobacterium bovis BCG vaccine responses across species, and we extend this work to determine whether a standardized MGIA can be applied in characterizing new TB vaccines. The comparative MGIA studies reviewed here aimed to evaluate robustness, reproducibility, and ability to reflect in vivo responses. In doing so, they have laid the foundation for the development of a MGIA that can be standardized and potentially qualified. A major challenge ahead lies in better understanding the relationships between in vivo protection, in vitro growth inhibition, and the immune mechanisms involved. The final outcome would be a MGIA that could be used with confidence in TB vaccine trials. We summarize data arising from this project, present a strategy to meet the goals of developing a functional assay for TB vaccine testing, and describe some of the challenges encountered in performing and transferring such assays.

Original languageEnglish (US)
Article numbere00142
JournalClinical and Vaccine Immunology
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Tuberculosis Vaccines
Assays
Growth
BCG Vaccine
Mycobacterium bovis
Tuberculosis
Biomarkers
Testing

Keywords

  • Correlates of immunity
  • MGIA
  • Mycobacterial growth inhibition assay
  • Tuberculosis
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Brennan, M. J., Tanner, R., Morris, S., Scriba, T. J., Achkar, J. M., Zelmer, A., ... Fletcher, H. A. (2017). The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014. Clinical and Vaccine Immunology, 24(9), [e00142]. https://doi.org/10.1128/CVI.00142-17

The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014. / Brennan, Michael J.; Tanner, Rachel; Morris, Sheldon; Scriba, Thomas J.; Achkar, Jacqueline M.; Zelmer, Andrea; Hokey, David A.; Izzo, Angelo; Sharpe, Sally; Williams, Ann; Penn-Nicholson, Adam; Erasmus, Mzwandile; Stylianou, Elena; Hoft, Daniel F.; McShane, Helen; Fletcher, Helen A.

In: Clinical and Vaccine Immunology, Vol. 24, No. 9, e00142, 01.09.2017.

Research output: Contribution to journalShort survey

Brennan, MJ, Tanner, R, Morris, S, Scriba, TJ, Achkar, JM, Zelmer, A, Hokey, DA, Izzo, A, Sharpe, S, Williams, A, Penn-Nicholson, A, Erasmus, M, Stylianou, E, Hoft, DF, McShane, H & Fletcher, HA 2017, 'The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014', Clinical and Vaccine Immunology, vol. 24, no. 9, e00142. https://doi.org/10.1128/CVI.00142-17
Brennan, Michael J. ; Tanner, Rachel ; Morris, Sheldon ; Scriba, Thomas J. ; Achkar, Jacqueline M. ; Zelmer, Andrea ; Hokey, David A. ; Izzo, Angelo ; Sharpe, Sally ; Williams, Ann ; Penn-Nicholson, Adam ; Erasmus, Mzwandile ; Stylianou, Elena ; Hoft, Daniel F. ; McShane, Helen ; Fletcher, Helen A. / The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014. In: Clinical and Vaccine Immunology. 2017 ; Vol. 24, No. 9.
@article{a8cdd3aeb9c447f691e42a2fddef1f18,
title = "The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014",
abstract = "The development of a functional biomarker assay in the tuberculosis (TB) field would be widely recognized as a major advance in efforts to develop and to test novel TB vaccine candidates efficiently. We present preliminary studies using mycobacterial growth inhibition assays (MGIAs) to detect Mycobacterium bovis BCG vaccine responses across species, and we extend this work to determine whether a standardized MGIA can be applied in characterizing new TB vaccines. The comparative MGIA studies reviewed here aimed to evaluate robustness, reproducibility, and ability to reflect in vivo responses. In doing so, they have laid the foundation for the development of a MGIA that can be standardized and potentially qualified. A major challenge ahead lies in better understanding the relationships between in vivo protection, in vitro growth inhibition, and the immune mechanisms involved. The final outcome would be a MGIA that could be used with confidence in TB vaccine trials. We summarize data arising from this project, present a strategy to meet the goals of developing a functional assay for TB vaccine testing, and describe some of the challenges encountered in performing and transferring such assays.",
keywords = "Correlates of immunity, MGIA, Mycobacterial growth inhibition assay, Tuberculosis, Vaccines",
author = "Brennan, {Michael J.} and Rachel Tanner and Sheldon Morris and Scriba, {Thomas J.} and Achkar, {Jacqueline M.} and Andrea Zelmer and Hokey, {David A.} and Angelo Izzo and Sally Sharpe and Ann Williams and Adam Penn-Nicholson and Mzwandile Erasmus and Elena Stylianou and Hoft, {Daniel F.} and Helen McShane and Fletcher, {Helen A.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1128/CVI.00142-17",
language = "English (US)",
volume = "24",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - The cross-species Mycobacterial Growth Inhibition Assay (MGIA) project, 2010–2014

AU - Brennan, Michael J.

AU - Tanner, Rachel

AU - Morris, Sheldon

AU - Scriba, Thomas J.

AU - Achkar, Jacqueline M.

AU - Zelmer, Andrea

AU - Hokey, David A.

AU - Izzo, Angelo

AU - Sharpe, Sally

AU - Williams, Ann

AU - Penn-Nicholson, Adam

AU - Erasmus, Mzwandile

AU - Stylianou, Elena

AU - Hoft, Daniel F.

AU - McShane, Helen

AU - Fletcher, Helen A.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The development of a functional biomarker assay in the tuberculosis (TB) field would be widely recognized as a major advance in efforts to develop and to test novel TB vaccine candidates efficiently. We present preliminary studies using mycobacterial growth inhibition assays (MGIAs) to detect Mycobacterium bovis BCG vaccine responses across species, and we extend this work to determine whether a standardized MGIA can be applied in characterizing new TB vaccines. The comparative MGIA studies reviewed here aimed to evaluate robustness, reproducibility, and ability to reflect in vivo responses. In doing so, they have laid the foundation for the development of a MGIA that can be standardized and potentially qualified. A major challenge ahead lies in better understanding the relationships between in vivo protection, in vitro growth inhibition, and the immune mechanisms involved. The final outcome would be a MGIA that could be used with confidence in TB vaccine trials. We summarize data arising from this project, present a strategy to meet the goals of developing a functional assay for TB vaccine testing, and describe some of the challenges encountered in performing and transferring such assays.

AB - The development of a functional biomarker assay in the tuberculosis (TB) field would be widely recognized as a major advance in efforts to develop and to test novel TB vaccine candidates efficiently. We present preliminary studies using mycobacterial growth inhibition assays (MGIAs) to detect Mycobacterium bovis BCG vaccine responses across species, and we extend this work to determine whether a standardized MGIA can be applied in characterizing new TB vaccines. The comparative MGIA studies reviewed here aimed to evaluate robustness, reproducibility, and ability to reflect in vivo responses. In doing so, they have laid the foundation for the development of a MGIA that can be standardized and potentially qualified. A major challenge ahead lies in better understanding the relationships between in vivo protection, in vitro growth inhibition, and the immune mechanisms involved. The final outcome would be a MGIA that could be used with confidence in TB vaccine trials. We summarize data arising from this project, present a strategy to meet the goals of developing a functional assay for TB vaccine testing, and describe some of the challenges encountered in performing and transferring such assays.

KW - Correlates of immunity

KW - MGIA

KW - Mycobacterial growth inhibition assay

KW - Tuberculosis

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85028998833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028998833&partnerID=8YFLogxK

U2 - 10.1128/CVI.00142-17

DO - 10.1128/CVI.00142-17

M3 - Short survey

VL - 24

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 9

M1 - e00142

ER -